Temanogrel + Placebo

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Microvascular Obstruction

Conditions

Microvascular Obstruction

Trial Timeline

May 20, 2021 → Aug 31, 2022

NCT ID

NCT04848220

About Temanogrel + Placebo

Temanogrel + Placebo is a phase 2 stage product being developed by Pfizer for Microvascular Obstruction. The current trial status is terminated. This product is registered under clinical trial identifier NCT04848220. Target conditions include Microvascular Obstruction.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04915950	Phase 2	Terminated	Nov 3, 2021	Sep 2, 2022	Raynaud's Phenomenon Secondary to Systemic Sclerosis
NCT04848220	Phase 2	Terminated	May 20, 2021	Aug 31, 2022	Microvascular Obstruction

Competing Products

7 competing products in Microvascular Obstruction

See all competitors

Product	Company	Stage	Hype Score
Zibotentan + Placebo oral tablet	AstraZeneca	Phase 2	52
Lercanidipine + Valsartan + Nicorandil + Doxazosin + Moxonidin + Pindolol + Amiloride, hydrochlorothiazide	Novartis	Pre-clinical	23
Ranolazine + Placebo	Gilead Sciences	Approved	84
Ranolazine + Placebo	Gilead Sciences	Phase 2	51
SAR247799 + Placebo + Sildenafil + Acetylcholine	Sanofi	Phase 1	32
SAR407899 + Placebo + Adenosine + Regadenoson + 13N-ammonia + 82Rubidium	Sanofi	Phase 2	51
Felzartamab + Placebo	Biogen	Phase 2	49

Other Products from Pfizer